ABSTRACT-In dogs, no significant difference in the reduction of serum cholesterol was observed among three dosing regimens of pravastatin: once in the morning (3 mg/kg), once in the evening (3 mg/kg), and twice-daily (1.5 mg/kg x 2) for 21 days. In rabbits, pravastatin was administered at a dose of 50 mg/kg once-daily given in the evening or 25 mg/kg twice-daily for 14 days; the respective serum and liver choles terol levels were decreased by 41% and 7% in the once-daily dosing and by 51% and 11% in the twice-daily dosing. The amount of low density lipoprotein (LDL) receptor protein was increased 1.2-1.3-fold (P <0.05) by both treatments, and no significant difference was noted between these treatment regimens. In addition, there was no significant difference in the extent of up-regulated LDL receptor protein between once-daily dosing in the evening and once-daily dosing in the morning. In the experiments with rabbit hepatocytes, the up-regulated LDL receptor activity induced by preincubation with pravastatin was retained even 24 hr after the removal of pravastatin. These results suggest that the comparable efficacy of pravastatin between once and twice-daily treatment could be explained by retention of up-regulated LDL receptor activity for more than 24 hr in vitro and in vivo.
3-Hydroxy-3-methylglutaryl (HMG)-CoA reductase in hibitors are very effective in lowering serum cholesterol, in particular, low density lipoprotein (LDL) cholesterol, in most animal species including humans (1-5), and are now widely used for the treatment of hypercholesterol emia (6) . The mechanism of lowering serum cholesterol by HMG-CoA reductase inhibitors is now believed to be as follows: hepatic cholesterol depletion by inhibition of cholesterol synthesis may trigger the induction of hepatic LDL receptor, resulting in the stimulation of LDL removal from the blood, and may decrease the secretion of very low density lipoprotein (VLDL) choles terol (5, 7) . We (8, 9) and other investigators (10, 11) reported that pravastatin increased hepatic LDL receptor activity in normal or Watanabe heritable hyperlipidemic (WHHL) rabbits. Kovanen et al. (12) reported that when mevinolin (lovastatin), an HMG-CoA reductase inhibi tor, was administered to dogs, an increase in the number of hepatic LDL receptors rather than a reduction in cho lesterol synthetic rate in the liver was responsible for the enhanced clearance of LDL from blood.
Meanwhile, Hunninghake et al. (13) and Pan et al. (14) reported that once-daily pravastatin administration (40 mg) to patients with primary hypercholesterolemia was as effective as twice-daily dosing (20 mg x 2). They specu lated that the efficacy of once-daily administration could be explained by its long retention of up-regulated LDL receptor, in spite of the rather short half-life of pravasta tin (15 (Indianapolis, IN, USA). All other chemicals were of the highest grade commercially available. Pravastatin was obtained by microbial hydroxylation of ML-236B as described elsewhere (16) .
Animals
Beagle dogs: Male beagle dogs (5 6-months-old; Hazleton Research Products, Inc., Madison, WI, USA) were housed individually under normal lighting con ditions (lights on 6 a.m. to 6 p.m.). One group consisted of 6 animals. The animals had free access to water and were fed a commercial dog food (Type DS; Oriental Yeast Co., Tokyo) at 300 g per day. Pravastatin was orally administered in zelatin capsules once or twice a day (at 9 a.m. and/or at 4 p.m. in the evening). Venous blood was obtained 24 hr after the final administration in each treatment under the fasting condition.
Rabbits: Male New Zealand White rabbits (5-months old; Japan SLC, Shizuoka) were housed individually under normal lighting conditions (lights on 7 a .m. to 7 p.m.). One group consisted of 5 animals. The animals had free access to water and were fed 120 g normal diet per day. Pravastatin was orally administered at 9 a.m. and/or at 4 p.m.). On the last day of pravastatin admin istration, the animals were fasted during the subsequent experimental period. For determination of liver cholesterol, a 200-mg por tion was extracted with 2 ml of isopropyl alcohol in a Polytron (Kinematica GmbH, Steinhofhalde, Switzer land), and the cholesterol content in the extract was de termined as described above.
Preparation of cultured rabbit hepatocytes
Rabbit parenchymal hepatocytes were isolated from male New Zealand White rabbits (23-weeks-old) by 0.0507o collagenase (type H) perfusion of the liver by the method of Selgen (18) . The isolated cells (viability > 90%) were suspended in William's E medium contain ing 5% heat-inactivated fetal calf serum, 10-' M insulin, 10-8M glucagon, 2 x 10-5 M dexamethasone, 100U
penicillin/ml and 100 pg/ml streptomycin. Cells were inoculated at a density of 5 x 105 cells/ml in a collagen coated, 24-well plate and incubated at 371C in a hu midified 5% CO2 / 95% air atmosphere. After 1 hr, the medium was renewed to remove the detached cells, and the cells were incubated in the same medium for 18 hr before the start of the experiments.
1251 LDL preparation and determination of LDL receptor activity in cell culture Human LDL (1.019<d<1.063) and lipoprotein deficient serum (d> 1.25) were prepared by ultracentrifu gation (17). LDL was radioiodinated by the iodine monochloride method (19) at a specific activity of 190 300 ng/mg protein.
Rabbit parenchymal cells were preincubated at 37V for 48 hr with or without 2 pg/ml pravastatin in William's E medium containing 15% lipoprotein deficient serum, 10-' M insulin, 10-8 M glucagon, 2 x 10-5 M dexameth asone, 100 U penicillin/ml and 100 peg/ml streptomycin. After the preincubation, cells were incubated in the fresh medium deprived of pravastatin for a further appropriate time. For determination of LDL receptor activity, cells were incubated with 20 pg/ml of 125I-LDL in the presence or absence of 400 , tg/ml of non-labeled LDL for 1 hr at 37'C. After the incubation, the cells were washed 5 times with 50 mM Tris buffer (pH 7.4) containing 150 mM NaCI and 2 mg/ml of bovine serum albumin, followed by two washes with the same buffer without serum albumin. The cells were dissolved in 1 ml of 2 mM sodium dodecyl sulfate (SDS) followed by determination of LDL bound and internalized according to the method of Goldstein et al. (20) .
Monoclonal antibody
Mouse monoclonal antipeptide antibody (designated 15D3) was kindly provided by Dr. M. Kuwano, Kyushu University School of Medicine. This antibody was direct ed against a synthetic peptide corresponding to the 14 amino acids of the C-terminal sequence of the bovine cortex LDL receptor. This sequence is highly conserved among many animal species including rabbit, hamster, rat and humans (21) .
Preparation of liver membrane fractions and immunoblot analysis of LDL receptors
Rabbit liver was homogenized with a Polytron in 8 volumes of homogenizing buffer (20 mM Tris-HCI, 1 mM CaC12, 150 mM NaCI, 1 mM PMSF, 0.1 mM leupeptin, pH 8.0), and membrane fractions that sedimented be tween 8,000 and 100,000 x g were prepared. The mem branes were stored at 80'C until use. Membrane pellets prepared as above were suspended in 250 mM Tris-maleate (pH 6.0) / 2 mM CaC12 / 1 MM PMSF / 0.1 mM leupeptin and solubilized by adding an equal volume of 2% SDS / 10% (w/v) glycerol / 0.2% bromophenol blue and then applied without addition of ;3-mercaptoethanol and without heating to 6% poly acrylamide slab gels containing 0.1% SDS according to the method of Laemmli (22) . Electrophoresis was carried out at a constant current of 20 mA/slab gel for 3 hr.
The separated proteins were electrotransferred from the gels to polyvinylidene difluoride (PVDF) membranes according to the method of Beisiegel et al. (23) . The PVDF blots were blocked in buffer A (10 mM Tris-HCI (pH 7.4) / 150 mM NaCI / 5076 BSA) at 37C for 30 min, followed by overnight incubation with mouse monoclonal anti-LDL receptor antibody. The blots were incubated for 2 hr with buffer A containing 0.74 MBq 1251_ protein A, followed by washing as described above and air drying. Autoradiograms were obtained with a Bio Imaging Analyzer (BA100; Fujix, Tokyo).
Statistical analysis
Data from these studies were statistically analyzed by Student's t-test. Each reported value is a mean±S.E.M. Effect of pravastatin on serum lipid levels of beagle dogs by once or twice-daily dosing for 21 days (Table 1) The diurnal rhythm of hepatic cholesterol synthesis, with the peak occurring around midnight, is well known (24) . From this point of view, we examined the difference between once and twice-daily treatment; and in the once daily administration, we compared the treatment in the morning with that in the evening.
Pravastatin was administered at doses of 1.5 mg/kg twice a day or 3 mg/kg once a day either in the morning or evening for 21 days. Blood samples were obtained 24 hr after the final dosage. As shown in Table 1 , once-daily dosing in the morning or in the evening decreased serum cholesterol by 25% or 28%, respectively. Twice-daily dosing decreased serum cholesterol by 32%. There was no significant difference in the extent of reduction of serum cholesterol among the three treatment groups. Choles terol levels were preferentially decreased in VLDL plus LDL fractions. Phospholipid levels in each treatment group also showed a similar reduction to cholesterol in each lipoprotein fraction. Triglyceride levels in two treated groups (once in the evening and twice a day) were significantly reduced in the whole serum and VLDL plus LDL fractions, but showed no reduction in the HDL fractions. In the control group, lipoprotein lipid levels did not change throughout the experiment. Table 2 . Effects of administration of pravastatin for 14 days on plasma cholesterol levels and low density lipoprotein (LDL) receptor protein of normal rabbits by once or twice-daily dosing Effect of pravastatin on serum and liver cholesterol levels, and LDL receptor activity of rabbits by once or twice daily dosing (Table 2) Pravastatin was administered at the doses of 25 mg/kg twice a day or 50 mg/kg once a day in the evening for 14 days. In the clinical studies, blood was collected in the morning. According to this schedule, in the experiments using rabbits, blood samples were obtained on the morn ing of the next day after the final dosage: 24 hr after the morning dosage or 14 hr after the evening dosage.
When pravastatin was given once in the evening, serum and liver cholesterol were decreased by 41% (P<0.05) and 7%, respectively, as compared with the control levels. These reductions were almost to the same extent as the twice-daily dosage regimen (51% (P<0.01) and 11% (P<0.05), respectively). LDL receptors determined by immunoblotting analysis were significantly increased 1.2-1.3-fold in the above two treatment regimens. However, no statistical difference was observed between these two treatment regimens. We compared the extent of LDL receptor induction by the once-daily administration in the morning with that of the once-daily administration in the evening. There was no significant difference be tween these two groups (100± 1 in the evening versus 117 ± 8 in the morning, shown as arbitrary units). Fig. 1 . Effects of pravastatin on low density lipoprotein (LDL) receptor activity in rabbit hepatocytes. Rabbit hepatocytes were preincubated with (/) or without (0) 2 pg/ml pravastatin for 48 hr. After the preincubation, cells were replenished with fresh medium without pravastatin, and then they were incubated for the indicated time, followed by further incubation for 1 hr with 20 pg/ml 125I LDL. Specific LDL receptor activity was determined as described in Materials and Methods. *P<0.05, **P<0.01.
Retention of the up-regulated LDL receptor activity after preincubation with pravastatin in rabbit hepatocytes ( Fig. 1) Cholesterol synthesis in rabbit hepatocytes was inhibit ed dose-dependently and almost completely inhibited by 2 pg/ml pravastatin treatment (data not shown). When rabbit hepatocytes were preincubated for 48 hr with 2 pg/ml pravastatin, the LDL receptor activity was in creased 2.7-fold (Fig. 1, 0 time, 20.5:L2.0 ng/mg protein in untreated cells versus 55.1±3.7 ng/mg protein in treated cells). After pravastatin was removed, this up regulated LDL receptor activity decreased in a time-de pendent manner, and the activity was calculated to have a half-life of about 9 hr. In addition, even 24 hr after the drug removal, the up-regulated LDL receptor activity was still higher than that in untreated cells.
DISCUSSION
Several clinical studies on the efficacy and safety of once daily versus twice-daily HMG-CoA reductase inhibitor treatment in hypercholesterolemia have been reported (11, 12, 25, 26) . In these studies, researchers observed that twice-daily dosing was slightly more effective than once daily dosing in the evening, and once-daily dosing in the evening was slightly more effective than that in the morn ing, but that there was no statistically significant differ ence in the hypocholesterolemic effects in these three groups. Our results in beagle dogs were consistent with the former observations in individuals with primary hypercholesterolemia.
Our hypothesis is that this comparable efficacy of pravastatin among different dosage regimens seems to be due to the long retention of the up-regulated LDL recep tor, in spite of the short half-life of pravastatin. The half-life of pravastatin in rabbit serum was about 3 hr when pravastatin was orally administered (Nitanai et al., personal communication). In beagle dogs, the half-life of pravastatin was reported to be less than 3 hr by the deter mination of changes of plasma concentration of radio activity after oral administration of [14C] -pravastatin (27). In contrast, the up-regulated hepatic LDL recep tor in rabbits by pravastatin treatment remained at a higher level than that in the control group, both at 14 hr and 24 hr after the final dosage (Table 2 ). In addition, the groups treated with the three different dosage regi mens (once in the morning, once in the evening, or twice a day) showed similar up-regulated LDL receptor levels. This is the first report to see the retention of hepatic LDL receptor activity up-regulated by pravastatin in vivo. We also observed this long retention of up-regulated LDL receptor activity in rabbit hepatocytes. The half-life of the up-regulated LDL receptor activity after pravastatin treatment was calculated to be 9 hr, and this remained at a higher level than that of the untreated cells up to 24 hr (Fig. 1) The reason for the long retention of up-regulated LDL receptors, for more than 24 hr, might be explained by the following mechanism: When pravastatin was administer ed to inhibit the cholesterol synthesis, hepatic HMG-CoA reductase was induced (8) , owing to the liver cholesterol homeostasis. After pravastatin was metabolized, the induced HMG-CoA reductase led to the restoration of liver cholesterol. However, in consecutive administration of pravastatin, liver cholesterol levels were maintained at a lower level than that of the untreated group 24 hr after the last dosage of pravastatin (Table 2) . This phe nomenon, in addition to the long half-life of LDL receptors rather than that of pravastatin, might lead to the long retention of up-regulated LDL receptors in the liver.
The increase in LDL receptor protein in rabbits was modest (1.2-1.3 fold). Kume et al. (11) reported that LDL receptor activity was increased 1.5-fold when a 5010 decrease of total cholesterol was observed (52% decrease in VLDL plus LDL fraction) by pravastatin treatment in heterozygous WHHL rabbits. From these observations, a modest increase in LDL receptors by pravastatin treat ment might be efficient for reducing plasma LDL, the metabolite of VLDL. Although the percent decrease of VLDL plus LDL cholesterol was larger than that of HDL cholesterol by pravastatin treatment in beagle dogs, the reduction of plasma cholesterol levels resided in the HDL fraction (Table 1) . Ma et al. (29) observed the same phenomenon in hamsters and WHHL rabbits. They sug gested that the HDL lowering effects of pravastatin in these animals might be explained by the relative abun dance of apolipoprotein E in the HDL fractions. Such HDL might be bound and internalized through LDL receptors, resulting in the reduction of HDL cholesterol. HDL is the major cholesterol-carrying lipoprotein in beagle dogs and rabbits, and a relatively large amount of apolipoprotein E-containing HDL might be efficiently metabolized by the elevated LDL receptor.
In our experiments, we used a relatively higher dose in rabbits (50 mg/kg per day) than beagle dogs (3 mg/kg per day) for the following two reasons: First, there is a difference in sensitivity towards HMG-CoA reductase inhibitors between rabbits and beagle dogs as reported previously (2) . Beagle dogs were more sensitive to HMG CoA reductase inhibitor than rabbits. Secondly, it was necessary to clearly see the changes of some parameters concerned with lipid metabolism such as liver choles terol levels and hepatic LDL receptor activity. Duration of pravastatin treatment is also different between the two animals (21 days for beagle dogs versus 14 days for rab bits). We examined the time course of serum cholesterol reduction during pravastatin treatment at these dosages and observed that durations of treatment in both animals described above was sufficient to produce the maximum reduction (data not shown).
In conclusion, the comparable efficacy of pravastatin given by different dosage regimens, which seemed to be a general event in most animals, could be explained by the retention of up-regulated LDL receptor activity for more than 24 hr, in spite of the short half-life of pravastatin in serum, and also by the lack of any significant differences in the levels of hepatic LDL receptor activity among these dosage regimens. From the results of these animal experi ments, and also in humans (13, 14) , comparable hypocholesterolemic effects of pravastatin among differ ent dosage regimens could be explained by the long retention of hepatic LDL receptor.
